NASDAQ:CLLS - Cellectis Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $21.80
  • Forecasted Upside: 231.81 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.57
▼ -0.02 (-0.30%)

This chart shows the closing price for CLLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cellectis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLLS

Analyst Price Target is $21.80
▲ +231.81% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cellectis in the last 3 months. The average price target is $21.80, with a high forecast of $33.00 and a low forecast of $10.00. The average price target represents a 231.81% upside from the last price of $6.57.

This chart shows the closing price for CLLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Cellectis. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$39.00 ➝ $16.00High
12/14/2021JMP SecuritiesReiterated RatingBuyHigh
12/14/2021Robert W. BairdReiterated RatingHold$10.00High
12/8/2021JMP SecuritiesReiterated RatingBuy$20.00Low
11/30/2021JMP SecuritiesInitiated CoverageOutperform$20.00Medium
11/8/2021William BlairDowngradeOutperform ➝ Market PerformMedium
10/17/2021Robert W. BairdReiterated RatingHold$10.00Medium
10/8/2021Robert W. BairdDowngradeOutperform ➝ Neutral$39.00 ➝ $10.00High
8/20/2021JonestradingReiterated RatingBuy$30.00Medium
6/3/2021OppenheimerInitiated CoverageBuy$33.00Low
6/1/2021William BlairReiterated RatingBuyHigh
5/27/2021Robert W. BairdReiterated RatingBuy$39.00High
5/4/2021GuggenheimReiterated RatingBuy ➝ NeutralN/A
4/29/2021Robert W. BairdReiterated RatingBuy$39.00High
4/28/2021GuggenheimDowngradeBuy ➝ NeutralHigh
3/16/2021Robert W. BairdUpgradeNeutral ➝ Outperform$23.00 ➝ $39.00High
3/8/2021William BlairReiterated RatingOutperformHigh
11/18/2020William BlairReiterated RatingBuyMedium
10/15/2020Robert W. BairdDowngradeOutperform ➝ NeutralHigh
8/19/2020CitigroupUpgradeNeutral ➝ Buy$15.00 ➝ $32.00High
8/6/2020OppenheimerReiterated RatingBuy$33.00Medium
7/7/2020Robert W. BairdLower Price TargetOutperform$28.00 ➝ $21.00High
5/11/2020Robert W. BairdInitiated CoverageOutperform$20.00Medium
5/7/2020OppenheimerReiterated RatingBuy$35.00High
3/6/2020CitigroupBoost Price TargetNeutral$14.00 ➝ $16.00Medium
3/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$15.00 ➝ $11.00High
2/19/2020BTIG ResearchBoost Price TargetBuy$37.00 ➝ $39.00High
1/13/2020William BlairReiterated RatingBuyHigh
12/16/2019Nomura SecuritiesReiterated RatingBuy$73.00Low
8/12/2019The Goldman Sachs GroupSet Price TargetHold$20.00High
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$37.00High
5/24/2019CitigroupReiterated RatingNeutral ➝ Neutral$22.00Medium
3/13/2019William BlairInitiated CoverageOutperformMedium
3/13/2019BarclaysReiterated RatingBuy$50.00High
3/11/2019CitigroupLower Price TargetNeutral$37.00 ➝ $22.00High
12/19/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00High
11/25/2018OppenheimerSet Price TargetBuy$44.00Low
7/16/2018BarclaysInitiated CoverageOverweight$50.00High
6/12/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $44.00Low
3/16/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
3/14/2018Nomura SecuritiesBoost Price TargetBuy$73.00High
12/28/2017OppenheimerReiterated RatingOutperform$40.00 ➝ $40.00Low
10/29/2017Jefferies Financial GroupReiterated RatingBuy$47.00N/A
10/6/2017SunTrust BanksReiterated RatingHold$20.00N/A
9/26/2017Jefferies Financial GroupReiterated RatingBuy$47.00Low
9/6/2017Nomura SecuritiesLower Price TargetBuy$49.00 ➝ $43.00Low
9/5/2017SunTrust BanksDowngradeBuy ➝ Hold$35.00 ➝ $20.00High
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$33.00 ➝ $40.00High
8/25/2017Jefferies Financial GroupSet Price TargetBuy$47.00High
6/3/2017OppenheimerReiterated RatingBuyLow
5/10/2017OppenheimerSet Price TargetBuy$40.00Low
4/26/2017Jefferies Financial GroupReiterated RatingBuy$47.00Low
3/21/2017OppenheimerReiterated RatingBuyLow
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$49.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
2/28/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformN/A
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/30/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/28/2021
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Cellectis logo
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More

Today's Range

Now: $6.57
Low: $6.32
High: $6.83

50 Day Range

MA: $8.17
Low: $6.57
High: $9.44

52 Week Range

Now: $6.57
Low: $6.00
High: $32.25

Volume

252,183 shs

Average Volume

285,030 shs

Market Capitalization

$298.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectis?

The following equities research analysts have issued reports on Cellectis in the last year: Guggenheim, JMP Securities, Jonestrading, Oppenheimer Holdings Inc., Robert W. Baird, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CLLS.

What is the current price target for Cellectis?

5 Wall Street analysts have set twelve-month price targets for Cellectis in the last year. Their average twelve-month price target is $21.80, suggesting a possible upside of 231.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting CLLS will reach $33.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $10.00 for Cellectis in the next year.
View the latest price targets for CLLS.

What is the current consensus analyst rating for Cellectis?

Cellectis currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLLS, but not buy more shares or sell existing shares.
View the latest ratings for CLLS.

How do I contact Cellectis' investor relations team?

Cellectis' physical mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company's listed phone number is (318) 169-1600 and its investor relations email address is [email protected] The official website for Cellectis is www.cellectis.com.